poisar

Stocks · News reference

Barclays Maintains Overweight on Hims & Hers Health, Lowers Price Target to $35

Benzinga Newsdesk

Barclays analyst Glen Santangelo maintains Hims & Hers Health (NYSE:HIMS) with a Overweight and lowers the price target from $39 to $35.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

HIMS
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Kaplan Fox & Kilsheimer Llp

    Kaplan Fox Encourages Investors of Hims & Hers Health, Inc. (NYSE: HIMS) Who Suffered Losses to Contact the Firm Before November 2, 2026

    Kaplan Fox has filed class action lawsuits against three companies: Hims & Hers for allegedly failing to disclose immediate prescription charges, sharing health data with third parties, and making subscription cancellations difficult; Hyliion Holdings for undisclosed issues during May-June 2026; and Innventure for regulatory concerns from November 2025 to August 2026. Investors with losses are encouraged to contact the firm before respective deadlines.

    HIMSHYLNINV
  2. Hagens Berman

    Hims & Hers Health (NYSE: HIMS) Faces Securities Class Action After FTC Lawsuit Reveal Drives Stock Sharply Lower -- HBSS

    Hims & Hers Health (NYSE: HIMS) faces a securities class action lawsuit following an FTC complaint alleging the company engaged in deceptive health data sharing with advertising platforms like Meta and Snap, and violated billing regulations by charging consumers for prescriptions before medical consultations. The lawsuit, filed by the FTC alongside Utah and Los Angeles County, also accuses Hims of using dark patterns to prevent subscription cancellations. The stock dropped 14.7% ($4.32) on July 29, 2026, erasing over $970 million in market value.

    HIMSMETASNAP
  3. Na

    HIMS Raises 2026 Revenue Outlook as Q2 Sales Rise 38.2% Despite Loss

    Hims & Hers reported Q2 2026 revenue of $753.2M, up 38.2% YoY, driven by subscriber growth to 2.9M and higher spending per subscriber. The company raised full-year 2026 revenue guidance to $3.1B-$3.3B (32-41% growth). However, gross margins contracted sharply to 63.8% due to lower-margin weight loss products and international expansion, resulting in an $86.3M net loss and widening loss per share estimates.

    HIMSNVOLLY